



Biochemical Pharmacology, Volume 77, issue 10, 15 May 2009

Contents

COMMENTARY

Non-ATP competitive protein kinase inhibitors as anti-tumor therapeutics

1561–1571

Lindsay O. Kirkland and Campbell McInnes

Linking anemia to inflammation and cancer: The crucial role of TNF α

1572–1579


Isabelle Buck, Franck Morceau, Christina Grigorakaki, Mario Dicato and Marc Diederich

ANTIBIOTICS AND CHEMOTHERAPEUTICS

Impact of alendronate and VEGF-antisense combined treatment on highly VEGF-expressing A431 cells

1850–1585


Medge Mongerard-Coulanges, Evelyne Migianu-Griffoni, Marc Lecouvey and Béatrice Jolles



The kinase inhibitor O⁶-cyclohexylmethylguanine (NU2058) potentiates the cytotoxicity of cisplatin by mechanisms that are independent of its effect upon CDK2

1586–1592

Luke R.E. Harrison, Christopher J. Ottley, D. Graham Pearson, Céline Roche, Stephen R. Wedge, M. Eileen Dolan, David R. Newell and Michael J. Tilby




CARDIOVASCULAR PHARMACOLOGY

Ras inhibition attenuates myocardial ischemia– reperfusion injury

1593–1601


Rakefet Pando, Yelena Cheporko, Ronit Haklai, Sofia Maysel-Auslender, Gad Keren, Jacob George, Eyal Porat, Alex Sagie, Yoel Kloog and Edith Hochhauser




Analogs of MK-499 are differentially affected by a mutation in the S6 domain of the hERG K⁺ channel

1602–1611

Jerzy Karczewski, Jixin Wang, Stefanie A. Kane, Laszlo Kiss, Kenneth S. Koblan, J. Christopher Culberson and Robert H. Spencer
Mutation of the S6 pore residue F656A in the hERGchannel dramatically reduces the potency of MK-499 but does not reduce the potency of the ketoneanalog L-702,958.






hSET1: A novel approach for colon cancer therapy

1635–1641

Sushma Yadav, Jyotsana Singhal, Sharad S. Singhal and Sanjay Awasthi

hSET1, a key element of histone-methyl transferases complex, has been shown to be a novel target for colon cancer therapy.




In vitro studies on the metabolism of trabectedin (YONDELIS®) in monkey and man, including human CYP reaction phenotyping

1642–1654

Marc Vermeir, Alex Hemeryck, Filip Cuyckens, Andres Francesch, Marc Bockx, Jos Van Houdt, Kathleen Steemans, Geert Mannens, Pablo Avilés and Roland De Coster

The *in vitro* metabolism of ^{14}C -trabectedin is qualitatively similar in monkey and man. Biotransformation occurs predominantly at its A subunit. At clinically relevant levels, CYP3A4 is the main CYP involved.



INDEXED/ABSTRACTED IN: *Curr. Cont.* ASCA, Biosis Data, CAB Inter., Chemical Abstracts Service, *Curr. Cont./Life Sci.*, CABS, EMBASE/Excerpt. Med., *Curr. Cont.* ISI/BIOMED Database, MEDLINE, PASCAL-CNRS Data, *Curr. Cont. Sci. Cit. Ind.*, *Curr. Cont.* SCISEARCH Data, Ind. Med., Reference Update. Also covered in the abstract and citation database SCOPUS®. Full text available on ScienceDirect®.



Available online at
 ScienceDirect
www.elsevier.com/locate/biochempharm